Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for the warning!
Really? OTC Markets Group Inc. ("OTC Markets") has discontinued the display of quotes on www.otcmarkets.com for this security because it has been labeled Caveat Emptor (Buyer Beware).
Check this URL: GIFX Gifa, Inc. - Buyer Beware
Wow! This is not looking good.
And with excellent feedback! Great!
I agree!
That is good News!
I really think they will succeed! GL2U2!
That is really good news. ADM Tronics has launched its first product - Tinnitus & Hearing Shield.
I hope soon it will be launching and distribution of Aurex-3 throughout the US and Europe. Sounds good!
Thanks for letting me know about ADM Tronics Receives Fast 50 Award!
Wow, that is good news!
I really believe that ADMT will succeed. I am hoping for the best.
Interesting Video: Digitizing Electronic Medical Devices - ADM Tronics, Sounds Good!
Revive Therapeutics Appoints Blockchain Expert, Bernie Doyle, as Technical Advisor to Support Development of Medical Cannabis Patient-Focused Program Enabled by Blockchain and AI Technology
TORONTO, ONTARIO--(Marketwired - Nov. 21, 2017) - Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on the research, development and commercialization of novel therapies and technologies for the medical cannabis and pharmaceutical sectors, today announced that Mr. Bernie Doyle will join the Company as a Technical Advisor to support the development of the Company's proposed proprietary patient-focused program enabled by blockchain and artificial intelligence ("AI") dedicated to the medical cannabis sector.
"I am pleased that Bernie has joined Revive to assist with the development of our proposed patient-focused solution driven by blockchain and artificial intelligence, that will provide licensed producers of medical cannabis and healthcare professionals unique tools and authentic information to support their objective of giving the highest possible quality of care to patients," said Fabio Chianelli, President of Revive. "Bernie has significant experience and knowledge in the field of software and blockchain development and design. He will be instrumental in assisting Revive's initiatives in the development of a novel technology solutions to support our future medical cannabis products, healthcare professionals and licensed producers of medical cannabis."
"I am very excited to be a part of the Revive team as we work to develop a one-of-a-kind technology solution for the medical cannabis sector," said Bernie Doyle, Blockchain Technical Advisor for the Company. "I am pleased to utilize my expertise to pave the way for a proprietary blockchain technology solution that will ultimately drive the development and the use of novel, safe, consistent, and effective cannabinoid-based therapeutics."
The potential of a patient-focused program enabled by blockchain and AI technology for the medical cannabis sector is significant. Blockchain technology unlocks the potential to ensure the security of shared information, such as clinical data and user data throughout the product lifecycle, and allows for the potential of personalized care by enabling patients, healthcare professionals, researchers and licensed producers of medical cannabis to collaborate, to innovate and develop medical cannabis products in treating specific medical disorders, and to deploy individualized cannabis-based therapies based on authentic evidence of use of proprietary medical cannabis products, which is an important aspect of cannabis treatment due to the various cannabis strains and ratios that can be produced to provide optimal care to patients.
Bernie Doyle is a Certified Ethereum Blockchain Developer and owner of Refine Labs, a blockchain advisory, architecture and development company, and he is currently president of the Government Blockchain Association - Toronto chapter. With nearly 10 years of software development experience, Mr. Doyle has been also dedicated in delivering advanced educational presentations on ground-breaking software and cloud-based solutions, blockchain, distributed ledger technology and smart contracts for a number of sectors, including fintech and healthcare. Mr. Doyle is a thought leader in the field of blockchain and he is dedicated to being a leader in connecting and educating government, organizations, businesses and individuals about blockchain, and he is focused on developing novel uses of blockchain to a variety of sectors.
I would like to know why it is going up too fast.
HedgePath Pharmaceuticals - Undiscovered, Underfollowed, And Undervalued
SUBA-Itraconazole likely approved in the first half of 2019 for Basal Cell Carcinoma Nevus Syndrome; interim data looks extremely positive on efficacy and safety.
Potential best-in-class Hedgehog Inhibitor compared to Roche's Erivedge (vismodegib) and Sun Pharma's Odomzo (sonidegib), and a lot cheaper at an anticipated ~$60k/year vs. ~$150k/year for those drugs.
Equity capital raise, possible exchange uplisting from OTCQX, possible sell-side coverage, and initiation of second clinical trial in lung and/or prostate cancer in 2018 could all improve investor awareness.
Note: Be advised that this article contains medical imagery that some might consider graphic.
Background
HedgePath Pharmaceuticals (OTCQX:HPPI) is a Tampa-based clinical stage biopharmaceutical company focused currently on repurposing the marketed antifungal drug itraconazole for new indications in oncology. HPPI recently announced enrollment completion of its Ph. II(b) trial of a proprietary SUBA-Itraconazole capsule in Basal Cell Carcinoma Nevus Syndrome (BCCNS). The company would like to file an NDA sometime in the second half of 2018 after a pre-NDA meeting with the FDA around the middle of 2018, barring any feedback from the FDA that suggests the Ph. II(b) data alone would not be sufficient for subsequent FDA approval. HPPI was granted Orphan Drug Designation for SUBA-Itraconazole for the treatment of patients with BCCNS in June 2016 due to a lack of any approved treatment for BCCNS currently.
HPPI was formed from the reorganization of Commonwealth Biotechnologies, Inc. following its exit from Chapter 11 voluntary bankruptcy in August 2013. Essentially, Commonwealth Biotechnologies was a corporate shell and private equity firm Hopkins Capital Group acquired the shell with a new business plan and focus on taking a long-used anti-fungal drug (itraconazole) and repurposing it for cancer treatment. HPPI currently trades on the OTCQX Market, though management could seek to uplist to the NASDAQ or NYSE.
As of 9/30/17, HPPI had ~370 million shares outstanding, and based on a closing price of $0.36/share on 11/7/17, the company's market cap is $133M. Assuming the exercise of all outstanding options and warrants, the fully diluted share count would be ~427 million and the company would receive an additional ~$6.4 million in cash proceeds from the exercises.
Itraconazole - Anti-Fungal Treatment and Now a Cancer Agent?
Itraconazole, a triazole antifungal sold by a number of generic companies now following Janssen Pharmaceuticals's patent expirations, is normally administered as capsules, tablets, or as an oral solution. It is widely used in the prevention and systemic treatment of a broad range of fungal infections, including aspergillosis, blastomycosis, candidiasis, and histoplasmosis. Importantly, Itraconazole is different from other azole antifungal agents in that it is the only inhibitor in this class that inhibits both the hedgehog signaling pathway (discussed later in the report) and angiogenesis. Quite a bit of clinical work with itraconazole has been conducted in dozens of trials over the years by various investigators in various cancers, including basal cell carcinoma (BCC), prostate cancer, Non-Small Cell Lung Cancer (NSCLC), breast cancer, ovarian cancer, and glioblastoma, just to name a few. Generally speaking, the conclusion from many of these trials, as best summarized in this journal article, was that itraconazole may be effective in cancer treatment either as monotherapy or in combination therapy, though certainly additional clinical work would be necessary to obtain FDA approval for such indications.
HPPI and Mayne Pharma Relationship
Shortly after HPPI was formed in August 2013, the company announced a Supply and License Agreement with Mayne Pharma International Pty Ltd (OTCPK:MAYNF), an Australian-based and ASX-listed specialty/generic pharmaceutical company, whereby HPPI was named the exclusive U.S. licensee of Mayne's SUBA-Itraconazole for the treatment of cancers and Mayne Pharma would be responsible for manufacturing its proprietary formulation of an improved version of itraconazole, termed SUBA-Itraconazole. Following a couple of rounds of equity financings in June 2014 and May 2015, HPPI began its Ph. II(b) clinical trial in BCCNS with SUBA-Itraconazole in September 2015.
The company recently announced that it completed its Ph. II(b) trial enrollment of 38 patients and was taking steps to lock the trial's database in preparations for a future meeting with the FDA in spring 2018 and, in all likelihood, a subsequent NDA filing in BCCNS thereafter. HPPI's regulatory strategy is driven by the 505(b)(2) regulatory pathway, given that itraconazole has already been approved for use in humans for anti-fungal applications and has a long history of safe and efficacious use in that regard and because the company is developing an improved version of itraconazole as an anti-cancer agent. HPPI either owns outright or has exclusive licenses regarding the use of SUBA-Itraconazole as an anti-cancer therapy as well as the manufacturing and composition of matter for SUBA-Itraconazole for anti-cancer therapy.
As stated before, HPPI is the exclusive U.S. licensee of SUBA-Itraconazole for the treatment of cancer from Mayne Pharma. While possibly a bit unknown here in the U.S., Mayne Pharma has a $1B market cap and generated ~$440M in revenue in its FY17 (ending 6/30/17), more than double its revenue in FY16. While Mayne Pharma has worldwide operations and revenue from many countries, it has been increasing its focus on the U.S. market over the past few years, especially in its generic division. It may be worth noting that Mayne Pharma is one of the defendants in the ongoing generic drug price-fixing litigation in the U.S. against many generic manufacturers.
Mayne Pharma's patented SUBA-Itraconazole is based on its SUBA (stands for "super bioavailability") drug delivery technology that:
1. Improves the solubility/absorption of SUBA-Itraconazole in the body and allows for 90% bioavailability vs. generic itraconazole's 55% bioavailability due to its polymer drug dispersion technology
2. Allows for SUBA-itraconazole absorption regardless of stomach acidity conditions or in patients with acid reflux and taking proton-pump inhibitors (such as Nexium or Prilosec)
3. Reduces the variability of SUBA-Itraconazole levels within and between patients compared to generic itraconazole
4. Allows SUBA-Itraconazole to be taken either with or without food or acidic beverages
Thus, all these factors contribute to SUBA-Itraconazole being well-suited for chronic use in treating cancer due to its improved absorption, predictable therapeutic levels and clinical response, and reduction in the active drug quantity needed to deliver the required therapeutic blood levels, which decreases the toxic side effects when compared to generic itraconazole.
Outside of the U.S., Mayne Pharma markets SUBA-Itraconazole in Australia as an improved anti-fungal treatment and has out-licensed it in over 15 countries around the world. One would expect Mayne Pharma or its license partners to seek regulatory approvals for SUBA-Itraconazole for cancer treatment indication(s) outside the U.S. following FDA approval, likely piggy-backing off of clinical work performed by HPPI in the U.S.
Beyond its role as the SUBA-Itraconazole manufacturer and supplier, Mayne Pharma is also the majority stockholder of HPPI and owns 53.4% of the common shares outstanding as of 9/30/17 and 51.7% of the company on a fully diluted basis assuming the exercise of all options and warrants. Mayne Pharma may terminate the Supply and License Agreement between HPPI and Mayne Pharma if HPPI fails to achieve regulatory approval to commercialize SUBA-Itraconazole in the U.S. by 12/31/18. The implications of these last two statements will be discussed towards the end of the report.
Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome (BCCNS)
BCC accounts for ~80% of non-melanoma skin cancers diagnosed each year in the U.S., which means ~3.3 million BCC cases are diagnosed annually. BCC typically starts in the top layer of the skin and develops in areas regularly exposed to the sun and other forms of UV radiation, especially the neck and head areas. BCC is usually curable if the tumors are restricted to a small area of the skin, and surgical excision is the primary therapy used to treat BCC and has 5-year cure rates of 92-98%. Locally advanced BCC, or laBCC, refers to basal cancers that have not spread to other body parts but cannot be treated by surgery or radiation. It is estimated that laBCC occurs in 1%-10% of BCC patients, and that mBCC occurs in up to 0.5% of BCC patients. In HPPI's most recent 10-K, the company cites 65,000 BCC patients needing surgical treatment for facial tumors that require excision and potential plastic surgery, amounting to a $600 million potential market based on SUBA-Itraconazole's anticipated $5,000/month cost. Patients with mBCC have a median survival of 8 months.
BCCNS, sometimes referred to as Gorlin Syndrome or Gorlin-Goltz Syndrome, is a hereditary BCC disorder that affects an estimated 1 in 31,000 people. In the U.S., BCCNS is considered an orphan disease due to a patient population of just 10,000 people. The root cause of BCCNS is a genetic abnormality in the PTCH1 gene, which, for 90% of BCCNS patients, leads to a life-long formation of BCC tumors, often in the torso and facial areas (as seen in Figure 1), and numerous surgical excisions to remove such tumors. Repeated surgical excisions, especially those required in the facial region, are the standard of care in BCCNS and often lead to physical disfigurement and scarring. One of the primary characteristics of BCCNS is the development of multiple BCC tumors at an early age, often in adolescence, which is contrary to BCC, which often comes later in life after greater exposure to the sun during one's lifetime.
BCCNS is also responsible for the increased risk of development of other cancers early in a person's life, including medulloblastoma, breast cancer, non-Hodgkin's lymphoma, and ovarian cancer, not to mention other unique physical features as well (e.g., cleft palate, large head size, a protruding jaw, pitting in the palms of the hands/feet, skeletal abnormalities). Currently, there is no FDA approved therapy for BCCNS treatment, but since BCCNS patients may develop BCC symptoms much earlier in life than BCC patients, there is a great unmet need for a low-toxicity therapy to minimize surgical procedures and prevent new BCC lesions from forming. HPPI deems the BCCNS market to be a $300 million market opportunity in patients with High or Moderate tumor burdens (see Figure 2). Notably, this excludes the ~4,500 patients with Low Tumor Burden, which is almost half the 10,000 BCCNS patient population. It is unclear to what extent management thinks they can penetrate this Low Tumor Burden segment over time, but for starters, they are not including it in their initial total available market estimate.
Figure 2. Company's estimate of BCCNS Total Available Market (Source: HPPI's 8-K regulatory filing on 10/5/17)
Hedgehog Pathway
The Hedgehog signaling pathway transmits information to embryonic cells necessary for proper cell differentiation, growth, and survival. The appropriate activation of this molecular pathway plays an important role in the initiation, growth, and metastatic spread of many cancers, including both BCC and BCCNS, which represent the closest association with hedgehog signaling, as well as brain, GI, lung, breast, and prostate cancers. It is believed that abnormal activation of the hedgehog pathway leads to development of disease through the transformation of adult stem cells into cancer stem cells that give rise to the tumor.
Importantly, itraconazole inhibits the hedgehog pathway in a mechanism unique from other FDA-approved hedgehog inhibitors (vismodegib and sonidegib, discussed below). Furthermore, hedgehog signaling must be suppressed continuously to inhibit tumor development and growth. This is about as technical a discussion of the hedgehog pathway that is warranted for purposes of this investment article, but a more in-depth discussion of this pathway can be found here.
Competing Hedgehog Pathway Inhibitor Drugs
There are two Hedgehog Inhibitor oral drugs already approved for locally advanced BCC (laBCC) and/or metastatic BCC (mBCC): vismodegib and sonidegib.
Vismodegib (brand name: Erivedge) was developed by Genentech (a subsidiary of Roche (OTCQX:RHHBF)) and approved in January 2012 under the priority review program (i.e., six-month review time) of the FDA for patients with mBCC or laBCC that have recurred following surgery or who aren't candidates for surgery or radiation. Approval followed a single, single-arm Phase II trial with 104 patients enrolled and efficacy measured in 96 patients. The trial's primary endpoint was objective response rate (ORR), which measured 30% in patients with mBCC and 43% in patients with laBCC. All responses in the mBCC cohort (n=33) were partial responses. In the 63 patients with laBCC, 13 patients had complete responses (21%) and 14 patients had partial responses (22%). Adverse reactions occurring in more than 10% of patients were muscle spasms, alopecia (hair loss), dysgeusia (distorted taste), weight loss, fatigue, nausea, diarrhea, decreased appetite, constipation, vomiting, arthralgias (joint pain), and ageusia (loss of taste).
Grade 3 adverse reactions included weight loss, fatigue, muscle spasms, and decreased appetite. Of the patients in this trial, 21% were diagnosed with BCCNS, but importantly, 54% of these BCCNS patients dropped out of the trial due to intolerable side effects/toxicity. Vismodegib was the first FDA-approved drug for use in the advanced forms of the most common skin cancer (i.e., BCC). The recommended dose of vismodegib is one 150-mg capsule once daily, with or without food, and each capsule's average wholesale price (AWP) is $422 (or $154,000/year) vs. the initial price of $250/capsule. In 2016, vismodegib generated over $200M in worldwide net sales with 2/3 of this amount coming from the U.S. For what it's worth, here is the drug label for Erivedge.
Sonidegib (brand name: Odomzo) was developed by Novartis (and later sold to Sun Pharma in December 2016 for $175 million + milestone payments) and approved in July 2015 for laBCC that has recurred following surgery or radiation therapy. Similar to vismodegib, sonidegib was also approved after just a single, double-blinded Phase II trial (n=194 patients). There were two doses tested (n=66 @ 200mg and n=128 @ 800mg, both given once per day) in the sonidegib trial, but the higher dose had worse side effects/adverse events and more clinical discontinuations and dose interruptions from adverse events (not to mention a lower objective response rate of 45%), so only the 200 mg dose is FDA approved. As with vismodegib, the primary endpoint was objective response rate, and in the lower dose cohort of 66 patients, tumor reductions occurred in 38 patients (58%), three of which were complete response (5%).
Due to side effects and adverse reactions, 34% of patients in the 200mg cohort stopped treatment. At the 200mg approved dose, the most common side effects were muscle spasms, alopecia, dysgeusia, fatigue, nausea, diarrhea, decreased weight, decreased appetite, myalgia (muscle pain), abdominal pain, headaches, vomiting, and pruritus (itching). The recommended dose of sonidegib is one 200-mg capsule once daily on an empty stomach at least one hour before or two hours after a meal. Sonidegib's AWP cost per capsule is $402 (or $147,000/year). Odomzo revenue figures are a bit challenging to find, but the drug was apparently on an $80 million/year run rate in the U.S. as of 3Q16. For what it's worth, here is the drug label for Odomzo.
Additionally, both vismodegib and sonidegib come with a Black Box warning regarding embryo-fetal death and severe birth defects for pregnant patients. Neither vismodegib nor sonidegib are approved for BCCNS. It's also worth pointing out the low bioavailability of vismodegib (32%) and sonidegib (10%) in the body, which means higher-than-desired dosing is needed for efficacy, which also causes higher-than-desired side effects. By comparison, SUBA-Itraconazole has a 90% bioavailability.
Ph. II(b) Interim Data in BCCNS
As mentioned previously, HPPI recently completed enrollment of its open-label Ph. II(b) trial in BCCNS patients with its SUBA-Itraconazole oral capsule (150mg twice per day) at five treatment centers in the U.S. For those interested, here is the ClinicalTrials.gov database's webpage for HPPI's SUBA-Itraconazole BCCNS trial.
The primary endpoint of the trial is overall response rate (ORR) of BCC lesions up to 26 weeks, with a pre-specified threshold of 30% ORR. Secondary outcomes include safety/tolerance, duration of response, time to next surgical intervention, and number of new BCCs eligible for surgical removal, among others. Management previously released interim data updates in August 2016, October 2016, and May 2017 to go along with the recent update on Oct. 30, 2017.
Management expects to have top-line data available in December 2017 and, ideally, a pre-NDA submission meeting with the FDA around mid-2018. NDA submission would presumably soon follow this meeting at some point, barring any guidance from the FDA that is contrary to their feedback to date with the company, and assuming the final data package is consistent with the data the company has shared thus far.
HPPI enrolled 38 patients in the trial, and each patient was required to have at least 10 surgically eligible BCC tumors at the time of enrollment along with a history of prior BCC surgical excisions. In fact, the average patient in the trial had 195 BCC tumors removed from prior surgeries. In the Oct. 30, 2017, interim update, HPPI reported a 54% ORR (i.e., >30% reduction in tumor size) in 467 individual target tumors evaluated, including 28% of tumors that had a complete response (i.e., completely disappeared). Despite the extensive surgical history of the patients in the trial, just a single tumor of the 467 tumors analyzed required surgical excision.
Furthermore, the response rates has been quite durable, with 60% of responding lesions continuing to respond during ongoing treatment that exceeds one year on average. The patient dropout rate is just 11%, and the side effect profile has been very encouraging with no serious adverse events due to SUBA-Itraconazole or reports of hair loss, loss of taste, or disabling muscle cramps as seen with vismodegib and sonidegib, the other hedgehog inhibitors, in their trials. In its totality, this data seems quite superb: strong efficacy, a massive reduction in surgical excisions required vs. the patients' prior histories, and a relatively mild side-effect profile.
I will have patience and hoping they will succeed.
I am still here.
Revive Therapeutics Ltd. Announces Results for Fiscal Year Ended June 30, 2017
TORONTO, ONTARIO--(Marketwired - Oct. 19, 2017) - Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs in the medical cannabis and cannabinoid pharmaceuticals sectors, today announced its results for the fiscal year ended June 30, 2017. The Audited Financial Statements and Management's Discussion and Analysis for the year ended June 30, 2017, may be viewed on SEDAR at www.sedar.com.
"I am pleased with how our focus on developing and commercializing novel cannabinoid-based therapies has evolved over this past year," said Craig Leon, Chief Executive Officer of Revive. "The value creating initiatives achieved for our medical cannabis and cannabinoid pharmaceuticals strategy such as the exclusive license and the research of cannabinoid-based therapies for liver diseases, the development of a unique delivery technology for cannabinoids, the relationships with scientific advisors, academia and industry, and the potential of future collaborations with companies seeking to develop and commercialize novel cannabinoid-based therapies effectively positions Revive in the medical cannabis and cannabinoid pharmaceuticals space for broad and large market opportunities."
Over the past year Revive has been focused on developing novel therapies that target the endocannabinoid system and building a robust cannabinoid-based product pipeline which includes early stage research and development programs with the advancement of cannabinoid-based therapies for liver diseases and potentially late stage commercial opportunities with the development of a unique cannabinoid delivery system for the medical cannabis market. Revive continues to dedicate its resources in identifying and researching novel cannabinoid-based therapies and in developing its cannabinoid delivery technology for both near-term commercial opportunities in the medical cannabis market and long-term opportunities in the cannabinoid pharmaceuticals market.
Operational Activities Achieved in 2017:
Engaged scientific advisors for cannabinoid-based therapies for liver diseases such as Dr. Scott Friedman, MD, Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases, at the Icahn School of Medicine at Mount Sinai, Dr. Ram Subramanian, M.D, Associate Professor of Medicine and Surgery, and the Medical Director of Liver Transplantation at Emory Hospital and School of Medicine, Dr. Arun Sanyal, MD, Professor of Gastroenterology, Hepatology and Nutrition at the Virginia Commonwealth University (VCU) School of Medicine, and Dr. Pritesh Kumar, CEO PhytoSciences and an expert in cannabinoid pharmacology;
Entered into a research collaboration with Sanyal Biotechnology LLC for the development of cannabinoid-based therapies in the treatment of liver diseases such as autoimmune hepatitis (AIH), non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and fibrosis;
Entered into an exclusive license agreement with South Carolina Research Foundation for the development and commercialization of cannabidiol in the treatment of autoimmune disease, a rare liver disease;
Entered into an option to license agreement with Wisconsin Alumni Research Foundation for its Chitosan-Tannin delivery technology for the potential development and commercialization of a novel cannabinoid delivery technology; and
Entered into a sponsored research agreement with the University of Wisconsin-Madison to evaluate the Chitosan-Tannin delivery technology with a focus on cannabinoids for the potential to treat various diseases such as pain and skin disorders for the medical cannabis and cannabinoid pharmaceuticals markets.
Additional Operational Highlights
Revive announced the US FDA acceptance of its Investigational New Drug (IND) application and the initiation of the Phase 2 Study of REV-004 (Bucillamine) for the treatment of Cystinuria, and named Dr. David S. Goldfarb, MD, as Principal Investigator;
Revive announced the engagement of NYU School of Medicine and Massachusetts General Hospital for the Cystinuria Phase 2 Study;
Revive announced positive preclinical study results from its Rett Syndrome program; and
Revive Transferred the rights to the Rett Syndrome program to a third-party for an undisclosed one-time amount.
Financial Highlights
Cash and cash equivalents for the fiscal year ended June 30, 2017 totaled $1,768,676, compared to $1,333,239, for the year ended June 30, 2016;
Net loss for the fiscal year ended June 30, 2017 was $1,615,900, compared to a net loss of $2,737,932, for the year ended June 30, 2016. The decrease consisted primarily of research costs and professional fees; and
The Company's Research costs for the fiscal year ended June 30, 2017 were $408,216, compared to $1,568,288, for the year ended June 30, 2016.
About Revive Therapeutics Ltd.
Revive is focused on the research, development and commercialization of novel treatments for serious and unmet medical needs in the medical cannabis and cannabinoid pharmaceuticals markets by identifying and investigating potential therapies targeting the endocannabinoid system, such as cannabinoids, that may be repurposed for new indications, be delivered in a different way, combined with existing drugs, or be developed as new chemical entities. Additional information on Revive is available at www.ReviveThera.com.
Revive Therapeutics Announces Positive Results of its Novel Cannabinoid Delivery Technology
- Today announced positive initial results from its research project with the University of Wisconsin-Madison for the development of a novel cannabinoid delivery technology.
Revive Therapeutics Enters into Research Collaboration with Sanyal Biotechnology for Liver Diseases. Focused on advancing cannabinoids for the potential treatment of liver diseases.
Revive Therapeutics Applies to FDA for Orphan Drug Designation for Treatment of Autoimmune Hepatitis - Click here for more information
Revive Therapeutics and South Carolina Research Foundation Enter into Exclusive License Agreement for Cannabinoids-Based Therapeutics in the Treatment of Liver Diseases: Corporate Presentation
Sounds Good!
I read some: https://twitter.com/JNapodano
We will find out more about FDA feedback in August. I did not join Jason Napodano's subscription site.
I would also like to know who bought these shares so low and it does not sound good that it is not on the Sec's Edgar site yet.
New pathways to cancer therapy Repurposed antifungal agent exhibits promising efficacy and safety for BCCNS treatment
Nuo Therapeutics Restructures Series A Preferred Stock with Deerfield -
GAITHERSBURG, Md., June 12, 2017 (GLOBE NEWSWIRE)
Change to: (AURX) Nuo Therapeutics, Inc. Was (NUOTQ) Nuo Therapeutics.
HedgePath Pharmaceuticals Announces Granting of Type-C Meeting Request by FDA and Provides Positive Clinical Trial Update.
TAMPA, Fla., May 30, 2017 /PRNewswire/ -- HedgePath Pharmaceuticals, Inc. (HPPI)
They did have a 1/150 Split on 06/10/2015
I'm still interested in Pressure BioSciences.
Pressure Biosciences preps for up-list on US exchanges after Q1 earnings http://www.proactiveinvestors.com/companies/news/126118/pressure-biosciences-preps-for-up-list-on-us-exchanges-after-q1-earnings-126118.html
Thanks for the good news about PBIO!